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Introduction
Pediatric adrenocortical tumors (ACT) are rare, with an annual incidence of 0⋅34 cases per million children younger than 15 years (1) (2) (3) . ACT is more common among children who harbor germline TP53 mutations (e.g., Li-Fraumeni syndrome) or who have other tumor-prone constitutional syndromes (4) . Children with ACT usually develop symptoms related to increased production of androgens, corticosteroids, aldosterone, and estrogens, and approximately 80% present with virilization.
Complete tumor resection is the mainstay of effective treatment for pediatric ACT. Patients with local residual or metastatic disease have a dismal prognosis with mortality rates, around 50%, an outcome that has not significantly improved in the last 30 years (5-7). Children with advanced adrenocortical carcinoma (ACC) are typically treated with mitotane plus etoposide, doxorubicin, and cisplatin (EDP). Remarkably, the inclusion of EDP was originally based on a clinical trial of adult gastric carcinoma (8) and then adapted to the treatment of adults with ACC (9) (10) (11) . Two large prospective trials of EDP in adults with advanced ACC showed 49% and 23% overall response rates (10, 12) . The contribution of each individual agent in the EDP regimen to the overall disease response is controversial (13, 14) . Moreover, the acute and long-term complications of EDP are of concern for children with ACC. In particular, with the use of topoisomerase inhibitors such as doxorubicin and etoposide may result in leukemogenesis (15) .
Preclinical models have been extensively used to predict tumor responses, pharmacokinetics, and toxicity of compounds in humans. Although several human adult ACC cell lines have been successfully established in vitro and as xenograft tumors in mice (16) , there have been no such models for studying pediatric ACC. In this report we describe the establishment and characterization of the first human pediatric ACC xenograft model, which closely retains the genetic features and biological properties of the primary tumor. This pediatric ACC xenograft provides a unique opportunity to screen for new compounds and to study the signaling pathways that drive the growth and survival of these tumors.
Methods

Patients
Institutional review board approval and informed consents for establishing the xenograft were obtained. The conditions were in compliance with NIH Policies and Guidance for human subjects.
Establishment of xenograft tumor model
A primary sample of fresh human pediatric ACC was transplanted subcutaneously onto the flanks of male CB17 scid -/-mice (6-8 weeks old, Taconic Farms, Germantown, NY) as previously described (17) . The initial tissue transplant grew within 2 months and was maintained in vivo by subsequent serial passages into healthy mice. Xenograft tumor tissue was snap frozen in liquid nitrogen for molecular studies, and a fragment was fixed in 10% neutral buffered formalin for histologic studies.
Immunohistochemical analysis
Immunohistochemical analysis was performed on 4 µm sections of formalin-fixed, paraffinembedded tumor tissue using Benchmark XT (Ventana Medical, Tucson, AZ) and BondMax (Leica Microsystems, Bannockburn, IL) automated stainers with the reagents supplied by the manufacturers. The primary antibodies for CK8, p53, Ki-67, S-100, anti-human melanosome, inhibin, synaptophysin, and chromogranin A were used according to the recommendations of the suppliers. Appropriate positive and negative controls were included.
DNA fingerprinting
Genomic DNA was extracted from the primary and xenograft tumors, eluted in TE buffer (1 mM Tris and 0⋅1 mM EDTA, pH 8), and amplified for 16 genetic loci by the PowerPlex 16 System kit (Promega Corp., Madison, WI) following the manufacturer's recommendations. PCR amplified products were analyzed on a 3730 xl DNA Analyzer (Applied Biosystems, Foster City, CA) and resolved according to size (100 to 300 bases), giving an overall profile of short tandem repeat sizes (alleles).
Mutational screening for TP53 gene
Mutational screening was performed for the entire coding region (exons 2-11) and intron-exon boundaries of the TP53 gene by PCR and direct DNA sequencing. The primer sequences and program conditions for PCR analysis are available upon request.
RNA/protein extraction
Total RNA was extracted using the Qiagen RNeasy Midi kit (Qiagen, Valencia, CA). Agilent BioAnalyzer 2100 (Agilent, Palo Alto, CA) was used to assess the integrity of the total RNAs extracted from all of the samples. Tumor tissue lysates and whole-cell extracts were prepared using T-PER lysis buffer (Pierce Chemical, Rockford, IL) containing a complete protease- incubated for 1 h at 4ºC and centrifuged at 15,000 × g for 30 min at 4ºC. The supernatant was collected and frozen at -80ºC. Aliquots of supernatant were collected for protein quantification by the Bradford method (Bio-Rad protein assay, Bio-Rad Laboratories, Richmond, CA).
RNA expression profile
Affymetrix gene expression analyses were performed by the St. Jude Children's Research Hospital Hartwell Center for Bioinformatics and Biotechnology Core Facility using the Gene Chip U133v2 platform according to the manufacturer's recommendations (Affymetrix, Santa Clara, CA). Results from the primary and xenograft tumors were compared with normal adrenal cortex and a cohort of previously characterized ACTs using hierarchical clustering analysis as previously described (18) .
Protein analysis
Total protein (50 μg) was separated on 12% (wt/vol) polyacrylamide gel using the Novex NuPAGE system (Invitrogen, Carlsbad, CA), transferred to nitrocellulose membranes (Whatman GmbH, Dassel, Germany), and blocked with 5% non-fat milk in Tris-buffered saline Tumor status (e.g., progressive disease, relative tumor volumes, and event-free survival) was determined as previously reported (19) .
RESULTS
Clinical features of the pediatric ACC patient. Adrenocortical tumor tissue was obtained from
an 11-year-old boy with a right adrenal mass incidentally found during the work-up for abdominal trauma. Magnetic resonance imaging revealed a 9⋅7 × 8⋅6 cm right suprarenal mass that was resected and confirmed to be adrenocortical carcinoma. Clinical signs and symptoms of virilization or hypercorticism were not remarkable, although pubic hair (Tanner stage II) was noted. On admission, the patient was 43⋅1 kg (percentile 80) and 157⋅4 cm (percentile 96). Expression of mutant p53-G245C protein in the SJ-ACC3 xenograft was determined by Western blot analysis (supplementary figure 2) . High levels of p53 were detected in the xenograft compared with normal adrenal cortex, which is consistent with its strong nuclear staining in both the primary and xenograft tumors (figure 1). Furthermore, high molecular weight IGF2 (8⋅5 to 24 kDa), presumably precursor forms, was also found to be strongly expressed in the SJ-ACC3 xenograft (supplementary figure 2) , as expected for pediatric ACTs.
β-actin expression was used as a control for protein loading. Response to topotecan in a relapsed ACC patient. An adolescent girl presented with evidence of virilization and hypercortisolism at 15 years of age. She was found to have a left adrenal mass with metastatic deposits in the liver and lung. She underwent left adrenalectomy with removal of the liver metastases and was subsequently treated with EDP plus mitotane. At the end of eight cycles of therapy, there was no definitive evidence of residual disease, and therapy was discontinued. Approximately 3 months later, an enlarged epicardial lymph node was detected, consistent with recurrent, metastatic disease. After two courses of cyclophosphamide and topotecan following the Children's Oncology Group regimen (22) , the node significantly increased in size. Subsequent treatment with sorafenib also had little effect, and palliative care was considered. However, based on the topotecan schedule used in the preclinical xenograft model, intravenous topotecan targeted to an area under the curve of 100 ± 20 ng-h/mL for five days in two consecutive weeks (23) was administered every four weeks.
This single-agent regimen produced disease stabilization for the 4 months that it was administered. Due to severe myelosuppression and sepsis requiring intensive care unit support, treatment was discontinued. The patient survived an additional 8 months before succumbing to ACC progression.
Discussion
Here we report the establishment and characterization of the first pediatric adrenocortical xenograft model and evaluation of its response to selected chemotherapeutic drugs. (24) (25) (26) . Loss of heterozygosity with selection against the wild-type TP53 allele is common in pediatric ACC (4, 27) and was observed in both the primary and xenograft tumors. Affymetrix analysis also revealed similar patterns of gene expression between the primary and xenograft tumors, including the overexpression of IGF-2, and these profiles are consistent with ACC ( figure 2 and supplementary figure 2 a Kaplan-Meier estimate of median days to event determined using interpolated days to event. b p-values comparing event-free survival distributions between treated and control groups. c EFS (event-free survival) T/C is the ratio of the median time to event between treated and control groups. d Median final RTV (relative tumor volume) is the ratio of the tumor volume at the end of treatment to the volume at initiation of treatment. e Tumor volume T/C is the ratio of mean tumor volume of treated tumors divided by mean tumor volume of control tumors.
f "> EP" indicates that the median EFS for the treated group is greater than the evaluation period (EP).
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